U.S., March 18 -- ClinicalTrials.gov registry received information related to the study (NCT07478094) titled 'Longitudinal Outcomes of Patients With Group 3 Pulmonary Hypertension Treated With Iloprost' on Feb. 27.
Brief Summary: This observational real-world study aims to evaluate the longitudinal clinical outcomes of adult patients with Group 3 pulmonary hypertension (PH), associated with chronic lung diseases such as interstitial lung disease, who are treated with inhaled iloprost in routine clinical practice.
Treatment options for Group 3 PH remain limited, and the use of pulmonary vasodilators is controversial due to potential worsening of gas exchange. Inhaled iloprost may provide a more selective approach by targeting well-ventilat...